Clinical Trial Update: Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial update evaluating adjuvant therapy guided by pathologic response after neoadjuvant treatment with encorafenib and binimetinib in m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma Stage III, Melanoma Stage IV | EARLY_Phase 1 | Status: RECRUITING